Enzo Biochem (ENZ) Reports Q1 Loss of $0.13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Enzo Biochem Reports Fiscal First Quarter Results
December 10, 2019 4:15 PM ESTCompany Announces Plan to Unlock Value for Therapeutics Subsidiary
Announces Three Lab-to-Lab Relationships
Announces Appointment of New Chief Financial Officer
Enzo Continues to Take Steps in Creating New Model for Modern Day Diagnostics Company
NEW YORK--(BUSINESS WIRE)-- Enzo Biochem, Inc. (NYSE: ENZ), an integrated diagnostics and life sciences company focusing on delivering and applying advanced technology capabilities to produce affordable, reliable products and services that enable its customers to meet their clinical needs, today reported... More
